+34 679 490 537info@nanbiosis.com

Posts Taged biomedicine

Nucleic Acids Chemistry, new book release by Ramon Eritja

Ramón Eritja, Scientific Director of NANBIOSIS Unit 29 Oligonucleotide Synthesis Platform (OSP) has just published a new book “Nucleic Acids Chemistry, modifications and conjugates for Biomedicine and Nanotechnology“, Anna Avinó, Scientific Coordinator of NANBIOSIS Unit 29 is also a writer of the book.

The book “Nucleic Acids Chemistry” takes the most important aspects of the methodology of oligonucleotides synthesis, that is currently expanding by the endorsement of a dozen of new medicines, such as the first medicine based on interfering RNA for the control of LDL and cholesterol in blood that will facilitate the decrease of cardiovascular illnesses.

The writing of the book has been directed by Dr. Ramon Eritja, of Centro de Investigación en Red de Nanomedicina (CIBER-BBN) and is Research Professor at Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), being its director between 2012-2017. The co-authors are Carme Fàbrega, Anna Aviñó, Santiago Grijalvo, Andreia F. Jorge, from IQAC-CSICCarlos González from Instituto de Química Física Rocasolano (IQFR-CSIC) and Raimundo Gargallo from University de Barcelona  The book began to be written in mid-2019, although most of the book was written during the lockdown.

In the last five years, an expansion of technologies based on DNA and RNA in diagnosis and therapeutic use has been produced, and it has been very important in the research of quick solutions to avoid the COVID pandemic and, predictably, the research group’s environment has led the development of several solutions, like biosensors for the direct detection of SARS-CoV-2.

A former PhD student of Ramon Eritja group, Dr. Ramón Güimil García, Head of Synthetic Oligonucleotides bei BioNTech, has participated in the development of the BioNTech-Pfizer mRNA vaccine. Another doctor, Brendan Manning, formed member of the group, has participated in the development of a diagnosis kit named Sherlock, which uses the CRISPR-Caspasa system for the detection of the virus that causes COVID.

Dr Erija completed his doctoral thesis at the University of Barcelona directed by Dr. Ernest Giralt on the subject of peptide synthesis. In 1984 he carried out his first postdoc with Dr. Itakura at the Beckman Research Institute of City of Hope in Los Angeles where the production of the first synthetic genes was carried out, highlighting the production of synthetic insulin that, with the name of humulin, solved the problems generated from the use of swine insulin. In 1986 she completed the second postdoc with Dr. Caruthers at the University of Colorado at Boulder. In this laboratory, phosphoramidites were developed, which are the reagents used today for the production of synthetic DNA and RNA. Upon his return to Barcelona, ​​he joined the CSIC Research and Development Center where he organized the first research group in our country focused on oligonucleotide synthesis. In 1984 he moved to the European Molecular Biology Laboratory (EMBL) in Heidelberg (Germany) to direct for 5 years one of the most prestigious groups in DNA and RNA Chemistry in Europe. Upon his return to Barcelona, ​​he was part of the Barcelona Institute for Biomedical Research (IRB Barcelona) and was recognized as a group of excellence by the CIBER-BBN. In 2012 he moved to the IQAC-CSIC to occupy the direction of the institute until 2017.

Refernce:

Nucleic Acids Chemistry – Modifications and Conjugates for Biomedicine and Nanotechnology Edited by: Ramon Eritja. De Gruyter | 2021 DOI: https://doi.org/10.1515/9783110639537

The book can be purchased here: link

Read More

III Conference on the Disclosure of Biomedical and Experimental Sciences

The III Conference for the Disclosure of Biomedical and Experimental Sciences will take place at the Center for Minimally Invasive Surgery Jesús Usón of Cáceres, on December 5, 2019. It will be attended by Francisco Miguel Sanchez Margallo, Deputy Scientific Director of NANBIOSIS and Beatriz Moreno Lobato, Scientific Director of Unit 19 of NANBIOSIS

FREE ACTIVITY – Requires prior registration until full capacity is reached

Pre- registration: https://www.ccmijesususon.com/formacion/preinscripcion/1173/

Program:

Read More

«The combination of nanotechnology with bioengineering and biomedicine allows us to act on the human body on a molecular scale»

Josep Samitier, Scientific Director of NANBIOSIS Unit 7 Nanotechnology Unit, has been highlighted in ‘Dominical’ supplement of the Diari de Girona last week.

More information here 

Read More

Platform2nano research by Víctor Sebastián, (Unit 9 of NANBIOSIS) awarded Marie Skłodowska-Curie

The Platform2nano research project (2012-2016) has just been awarded a second prize in the “Contribution for a better society” category, at the “Mobility Takes Research Further” conference organized by Marie Skłodowska-Curie actions (MSCA 2017) in the framework of the Presidency of Malta of the Council of the European Union. More than 195 researchers from 30 nationalities who have developed their scientific work through the prestigious Marie Skłodowska-Curie Scholarships were presented to these awards.

The project “Development of a microfluidic platform to produce nanomaterials and assessment on new nanotechnology applications” in which participate the researchers Manuel Arruebo, Laura Usón, Isabel Ortiz de Solorzano y Jesús Santamaría members of the group Nanostructured Films and Particles -NFP, coordinator of Unit 9 of NANBIOSIS, was rated as excellent for its outstanding contribution to the design of a wide variety of nanomaterials through efficient technologies and for its multiple applications in different fields of great social interest such as biomedicine or energy processes.

Read More